Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer at ASCO GU 2016
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer at ASCO GU 2016